AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17134636
Drug: n-3 FA
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 FA supplementation (1 to 3.4 g/day) for 4 to 6 months
Trial: 15181294
Drug: Fast advancement
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast advancement (30 ml/kg/day)
Trial: 15181294
Drug: Slow advancement
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow advancement (15 ml/kg/day)
Trial: 7587605
Drug: Hirudo treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hirudo treatment
Trial: 2146242
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g spectinomycin (single intramuscular injection)
Trial: 2146242
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg erythromycin base (five-day oral course, three times daily)
Trial: 657032
Drug: Topical aerosol
RxNorm normalized name: Lidocaine Topical Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical aerosol spray containing neomycin sulfate, polymyxin B sulfate and zinc bacitracin
Trial: 31915035
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (control group starting at 2 years CA)
Trial: 30670238
Drug: Multicomponent intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multicomponent intervention (n = 41), 90-minute sessions of physical, cognitive, or social activities twice weekly
Trial: 28093370
Drug: G-EO
RxNorm normalized name: EO-3021
DrugBank: EO-3021 (DB18358)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-EO
Trial: 25749543
Drug: Dexamethasone sodium
RxNorm normalized name: dexamethasone sodium phosphate
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone sodium phosphate (DSP) cream applied to the right ear for 15 days
Trial: 25749543
Drug: Placebo-water in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-water in oil emulsion type cream applied to the left ear for 15 days
Trial: 19229603
Drug: ivabradine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivabradine therapy
Trial: 18274218
Drug: Sequential-timing tasks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential-timing tasks
Trial: 15807926
Drug: Endocrine agents
RxNorm normalized name: ENDOCRINE THERAPY ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine agents like aromatase inhibitors and luteinizing hormone-releasing hormone agonists
Trial: 8690815
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg twice daily of befloxatone
Trial: 8690815
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg once daily of befloxatone
Trial: 25751300
Drug: Alpha-Lipoic Acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-Lipoic Acid (ALA) 1200 mg/day for 8 weeks
Trial: 20951527
Drug: Short-axis approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-axis approach to ultrasound-guided peripheral intravenous access (USGPIV)
Trial: 20951527
Drug: Long-axis approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-axis approach to ultrasound-guided peripheral intravenous access (USGPIV)
Trial: 17099514
Drug: 4 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL/kg 7.5% NaCl
Trial: 17099514
Drug: 4 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL/kg 0.9% NaCl
Trial: 17099514
Drug: 32 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 32 mL/kg 0.9% NaCl
Trial: 1407911
Drug: Expectant management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expectant management plus antimicrobial therapy (intravenous ampicillin, gentamicin, and clindamycin for 24 hours, followed by amoxicillin plus clavulanic acid orally for 7 days.
Trial: 1407911
Drug: Expectant management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expectant management plus antimicrobial therapy
Trial: 30253776
Drug: Strength exercises
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength exercises embedded in physical education classes (15-30 min, 2x per week) plus monthly motivational lessons
Trial: 24958355
Drug: Telehealth device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telehealth device (electronic pill box)
Trial: 24958355
Drug: Passive medication
RxNorm normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive medication reminder devices (silent)
Trial: 16157523
Drug: High-dose methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methylprednisolone (3 monthly courses)
Trial: 1802636
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (66 mg elemental iron daily)
Trial: 21516496
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment + Tamsulosin (TAM)
Trial: 21516496
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment + Placebo
Trial: 12890302
Drug: Amisulpride (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride (100 mg b.i.d.)
Trial: 8606066
Drug: 0.8 ng
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 ng of Salmonella abortus equi endotoxin per kg of body weight administered intravenously at 0900 h
Trial: 25122647
Drug: Pregnant women
RxNorm normalized name: Hydroxyprogesterone Caproate 250mg/1mL Solution for injection [For Non-pregnant Women]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregnant women consuming 57 μg of dietary biotin/d
Trial: 25122647
Drug: Lactating women
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactating women consuming 57 μg of dietary biotin/d
Trial: 10022631
Drug: Formula UBT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula UBT with 270 ml of mixed formula meal (1 Kcal/ml)
Trial: 10022631
Drug: L-DOPA pretreatment
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-DOPA pretreatment (500 mg given 30 min before [13C]-urea load)
Trial: 2272718
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg acenocoumarol in combination with cimetidine
Trial: 2272718
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg acenocoumarol in combination with placebo
Trial: 2272718
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg acenocoumarol after one week pretreatment with pentobarbitone
Trial: 31786651
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 2400 mg
Trial: 30384775
Drug: Psychoanalytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoanalytic therapy (PAT)
Trial: 23879213
Drug: Oral oxycodone
RxNorm normalized name: oxycodone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oxycodone prescribed, tailored dosing regimen; measured urine concentration 10 to 14 days after starting treatment.
Trial: 23879213
Drug: Model for
RxNorm normalized name: Model AA 2012 KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model for predicting oxycodone in urine.
Trial: 9452696
Drug: Mouthwash based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mouthwash based on Zea mays L
Trial: 31152308
Drug: iv methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iv methylprednisolone (20 mg b.i.d)
Trial: 14709944
Drug: Atomoxetine (discontinued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (discontinued after 9 to 10 weeks of continuous therapy)
Trial: 14709944
Drug: Placebo (continuing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (continuing treatment)
Trial: 7934135
Drug: Baseline erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline erythropoietin level < 50 mU/ml
Trial: 3207009
Drug: Oral antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibiotics plus acute myringotomy (group B)
Trial: 3207009
Drug: Oral antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibiotics (group A)
Trial: 28817201
Drug: Biologics for
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologics for rheumatoid arthritis
Trial: 28817201
Drug: Different doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different doses of biologics
Trial: 26005963
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (250 mg bid)
Trial: 21418923
Drug: r‐bFGF eye-gel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r‐bFGF eye-gel, four times a day
Trial: 18482663
Drug: Low-flow-mediated constriction
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-flow-mediated constriction (L-FMC)
Trial: 11020033
Drug: Aerosolized standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized standard heparin (1.000 U/kg)
Trial: 11020033
Drug: Aerosolized LMWH
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerosolized LMWH (Enoksaparin, Clexane, 0.8 mg/kg)
Trial: 9244815
Drug: Gamma-linolenic acid
RxNorm normalized name: gamma-linolenic acid
DrugBank: Gamolenic acid (DB13854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamma-linolenic acid from borage seed oil (360 mg daily)
Trial: 3937220
Drug: Stored plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stored plasma (250-300 ml, n = 5)
Trial: 17277790
Drug: Cryotherapy during
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryotherapy during MTX administration
Trial: 17277790
Drug: No cryotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No cryotherapy during MTX administration (Control)
Trial: 15204668
Drug: Integrated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated treatment for co-occurring conditions
Trial: 31799861
Drug: ERAS protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERAS protocol with postoperative intravenous Flubiprofen Axetil or analgesia pump
Trial: 27861190
Drug: Dual acid-etched
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual acid-etched (DAE) implants
Trial: 25741159
Drug: Tissue selecting
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tissue selecting therapy stapler (TST)
Trial: 24474353
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group A (10 mL 17% EDTA and 10 mL 2.5% NaOCl)
Trial: 24474353
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group C (CanalBrush and 10 mL NaOCl)
Trial: 10340280
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (non-randomised arm, Control)
Trial: 1959402
Drug: Isoproterenol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol (5 mg)
Trial: 6752874
Drug: pirprofen 800
RxNorm normalized name: Carprofen
DrugBank: Carprofen (DB00821)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pirprofen 800 mg/day
Trial: 6752874
Drug: ketoprofen 300
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ketoprofen 300 mg/day
Trial: 24022237
Drug: Active oromucosal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active oromucosal nicotine spray (1 or 2 mg)
Trial: 18563517
Drug: High-dose L-alanyl-L-glutamine
RxNorm normalized name: L-Alanyl-L-glutamine
DrugBank: Alanyl glutamine (DB11876)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose L-alanyl-L-glutamine dipeptide [0.5 g/(kg day) glutamine]
Trial: 18563517
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with isonitrogeneous, isocaloric, isovolemic nutritional solution
Trial: 17330781
Drug: Paired samples
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paired samples collected before treatment and at recurrence of parasitemia.
Trial: 15496604
Drug: Milk-based formula
RxNorm normalized name: Formula, Infant Oral Powder for Suspension [TUGABOOS MILK-BASED FORMULA W/IRON]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk-based formula with 72 mg ribonucleotides/L (FN)
Trial: 9737454
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and Warfarin (WAR)
Trial: 2902545
Drug: Topical beta-blocker
RxNorm normalized name: Beta-HC Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical beta-blocker treatment
Trial: 28685397
Drug: 3QD regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3QD regimen (once daily: ombitasvir/paritaprevir/ritonavir and dasabuvir)
Trial: 28685397
Drug: 3‐DAA regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3‐DAA regimen (twice daily: ombitasvir/paritaprevir/ritonavir and dasabuvir)
Trial: 17657475
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment with decompression and various spondylodeses (n=13)
Trial: 17657475
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (n=6)
Trial: 15870625
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (21 g x d(-1))
Trial: 12215281
Drug: Usual drugs
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual drugs used in the clinic for 60 days
Trial: 11776765
Drug: Carboplatin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (100 mg, d 1-5) and 5-fluorouracil (500 mg, d 1-5) plus radiotherapy
Trial: 531541
Drug: Methylprednisolone (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (daily dosage)
Trial: 531541
Drug: Observation without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Observation without therapy (Control)
Trial: 24353023
Drug: Tapentadol ER
RxNorm normalized name: tapentadol Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol ER tablets (50, 100, 150, 200, or 250 mg)
Trial: 24353023
Drug: Tapentadol ER
RxNorm normalized name: tapentadol Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol ER tablets (250 mg) administered every 12 hours (five doses)
Trial: 24353023
Drug: Tapentadol ER
RxNorm normalized name: tapentadol Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol ER tablets (250 mg) with a high-fat meal
Trial: 24353023
Drug: Tapentadol ER
RxNorm normalized name: tapentadol Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol ER tablets (single dose)
Trial: 21464293
Drug: Human recombinant
RxNorm normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human recombinant leptin (metreleptin) in replacement doses over 36 weeks
Trial: 14702269
Drug: Continued perphenazine
RxNorm normalized name: Perphenazine
DrugBank: Perphenazine (DB00850)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continued perphenazine treatment
Trial: 11579988
Drug: Exposure therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure therapy (E)
Trial: 9360528
Drug: Hydrocortisone (HC)
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone (HC) infusions at a dose of 34-46 mg HC/24 h
Trial: 9360528
Drug: Hydrocortisone (HC)
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone (HC) infusions
Trial: 8432442
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 20 mg daily
Trial: 8432442
Drug: Prednisolone 40
RxNorm normalized name: prednisolone 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 40 mg daily (tapering to 10 or 20 mg)
Trial: 27022118
Drug: Crizotinib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crizotinib (250 mg twice daily; n = 172)
Trial: 27022118
Drug: Chemotherapy (pemetrexed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (pemetrexed 500 mg/m2 plus cisplatin 75 mg/m2 or carboplatin AUC 5 to 6; n = 171)
Trial: 24526744
Drug: Azithromycin 1.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 1.5% eye drops (twice daily for 3 days)
Trial: 24526744
Drug: Tobramycin 0.3%
RxNorm normalized name: TOBRAMYCIN 0.3% OINT,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin 0.3% eye drops (every 2 h for 2 days, then four times daily for 5 days)
Trial: 19783377
Drug: PCV chemotherapy
RxNorm normalized name: PCV
DrugBank: Penciclovir (DB00299)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PCV chemotherapy plus radiation therapy (PCV + RT)
Trial: 9848045
Drug: 0.5% silver
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% silver nitrate solution
Trial: 7924731
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg twice daily)
Trial: 23443788
Drug: Low-intensity ultrasound
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity ultrasound treatment for 30 min daily for 3 consecutive days
Trial: 23443788
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no particular treatments)
Trial: 22411387
Drug: Oral powder
RxNorm normalized name: Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral powder supplement enriched with eicosapentaenoic acid (1.5 g)
Trial: 22411387
Drug: Standard liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard liquid supplement
Trial: 9143748
Drug: Exercise treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise treatment (90 min/day of isotonic and isokinetic lower extremity exercise training)
Trial: 27566116
Drug: Waitlist control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waitlist control treatment
Trial: 24515352
Drug: CEPO (carbamylated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEPO (carbamylated EPO) 325 µg thrice-weekly
Trial: 16809804
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g P‐OM3
Trial: 8964410
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (group II)
Trial: 8964410
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (group IV)
Trial: 3856903
Drug: Vaginal film
RxNorm normalized name: Vaginal Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal film formulation containing 850 micrograms PGE2
Trial: 26938918
Drug: SnMP (4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SnMP (4.5 mg kg ‐1)
Trial: 20633511
Drug: Pharmacopuncture using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacopuncture using root bark of Ulmus davidiana Planch (UDP), administered twice a week for 6 weeks
Trial: 8276047
Drug: Flunitrazepam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam (1 mg) administered once daily for 8 days
Trial: 8276047
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered once daily for 8 days
Trial: 28877165
Drug: Unsupervised water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unsupervised water exercise twice a week for 12 weeks
Trial: 16462549
Drug: Manual-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual-based treatment for schizophrenia
Trial: 9291201
Drug: Candoxatrilat (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candoxatrilat (100 mg i.v. bolus)
Trial: 7687206
Drug: Thyroxine (150-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroxine (150-200 micrograms daily for 3 months)
Trial: 2942494
Drug: Flunitrazepam 2
RxNorm normalized name: flunitrazepam 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam 2 mg (after three repeated doses)
Trial: 27411009
Drug: Antibiotics (Vancomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (Vancomycin and Amoxicillin)
Trial: 20350945
Drug: MGAWN1 (0.3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MGAWN1 (0.3, 1, 3, 10, or 30 mg/kg)
Trial: 20350945
Drug: MGAWN1 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MGAWN1 (3 mg/kg)